Boku et al., J.clin Oncol. (1999), 79(5/6), 984-990 ABSTRACT ONLY.* |
Sugiyama et al., Cancer Lett. (Shannon, Irel.) (1998), 128(2), 211-218 ABSTRACT ONLY.* |
Kobayashi et al., Cancer Chemother. Pharmcol. (1998), 42(1), 53-58 ABSTRACT ONLY.* |
Mirabelli, C.K., et al., “A Murine Model to Evaluate the Ability of in Vitro Clonogenic Assys to Predict the Response to Tumors in Vivo”, Cancer Research, Official Journal of the American Association for Cancer Research, vol. 48, No. 19, pp. 5447-5454, Oct. 1, 1988. |
T.H. Corbett et al., “Evaluation of Single Agents and Combinations of Chemotherapeutic Agents in Mouse Colon Carcinomas,” Cancer, 40(5):2660-2680 (1977). |
T.H. Corbett et al., “Response of Transplantable Tumors of Mice to Anthracenedione Derivatives Alone and in Combination with Clinically Useful Agents,” Cancer Treatment Reports, 66(5):1187-1200 (May 1982). |
David L. Emerson et al., “In vivo Antitumor Activity of Two New Seven-substituted Water-soluble Camptothecin Analogues,” Cancer Research, 55:603-609 (Feb. 1995). |
Isabelle Madelaine et al., “Sequential Modifications of Topoisomerase I Activity in a Camptothecin-Resistant Cell Line Established by Progressive Adaptation,” Biochemical Pharmacology, 45(2):339-348 (1993). |
Tomio Furuta and Teruo Yokokura, “Combination Therapy of CPT-11, a Camptothecin Derivative, with Various Antitumor Drugs Against L1210 Leukemia,” Japanese Journal of Cancer and Chemotherapy, 18(3):393-402 (Mar. 1991); English Abstract p. 402. |
Abstract: Japio No. 00965715 for JP 57-116015. |
Abstract: Japio No. 00965774 for JP 57-116074. |
Abstract: Japio No. 01293588 for JP 59-5188. |
Abstract: Japio No. 01541290 for JP 60-19790. |
Abstract: Japio No. 02948687 for JP 1-246287. |
Abstract: Japio No. 02952177 for JP 1-249777. |
Abstract: Derwent No. 01984-110813/198418 for JP 59-051289. |
Masahiro Fukuoka and Noriyuki Masuda, “Clinical Studies of Irinotecan Alone and in Combination with Cisplatin,” Cancer Chemotherap. Pharmacology, 34(Suppl):S105-S111 (1994). |
Kensei Tobinai et al., “Combination Phase I/II Study of Irinotecan Hydrochloride (CPT-11) and Carboplatin in Relapsed or Refractory Non-Hodgkin's Lymphoma,” Jpn. J. Clin. Oncol., 26(6):455-460 (1996). |
A. Yokoyama et al., “Phase I/II Study of Irinotecan (CPT-11) and Cisplatin (P) Plus Concurrent Thoracic Radiation Therapy (TRT) in Stage III Non-Small Cell Lung Cancer (NSCLC: A Japan Clinical Oncology Group (JCOG) Trial,” Proc. Am. Soc. Clin. Oncol., 15(-):407 AB:1242 (1996). |